| Code | 7661D | ||||||||||
| MA number | 21/0145/21-S | ||||||||||
| Product Form: | cps dur 180x400 mg (blis.PVC/PVDC/Al) | ||||||||||
| MA Status: | D - Marketing Authorisation valid for an unlimited period | ||||||||||
| Type of procedure: | Mutual recognition procedure | ||||||||||
| Therapeutic Class: | 21 - ANTIEPILEPTICA, ANTICONVULSIVA | ||||||||||
| ATC: |
|
||||||||||
| Shelf life: | 24 | ||||||||||
| Route of admin.: | Oral use |
| Prescription Status: | Medicinal product subject to medical prescription. |
| Legal basis: | Article 10(1) generic application |
| MA issued: | 25.05.2021 |
| Pediatric indication: | Yes |
| Pediatric posology: | Yes |
| Pediatric warnings: | Yes |
| SPC: |
SPC_Gabapentin Glenmark 100_300_400 mg cps dur_07.2023.pdf
|
| PIL: |
PIL_Gabapentin Glenmark 100_300_400 mg cps dur_07.2023.pdf
|
| Safety feature | Yes |
| Data update: | 26.07.2023 |
